Myeloma Patients Europe

Startpagina
België
Brussels
Myeloma Patients Europe

Myeloma Patients Europe is an umbrella organisation of myeloma and AL amyloidosis patient groups

Myeloma Patients Europe (MPE) is an umbrella organisation of myeloma patient groups and associations from across Europe. MPE was formed following the merger in 2011 of the European Myeloma Platform and Myeloma Euronet. MPE is registered as a non-profit organisation (AISBL) under Belgian law and its headquarter is located in Brussels. MPE has a number of broad aims including:
• Collaborating on projects to the benefit of the myeloma community
• Exchanging information and best practice
• Developing existing patient groups and encouraging and facilitating the setting up of new groups
• Helping to shape appropriate health- related policies and initiatives on a European and national level
• Ensuring patients across Europe receive timely access to new treatment
• Stimulating and promoting patient- centred research and clinical trials
• Developing a strong evidence base for the needs and wants of patients and their role in research
• Providing information, educational and outreach programmes to member groups

To meet its aims and in addition to its membership, MPE works directly with healthcare professionals, reimbursement authorities, regulators, politicians, pharmaceutical companies, the media and anyone involved in the ‘myeloma community’.

11/09/2025

NEW RESOURCES: Myeloma and Infections

Infection is a major concern for myeloma patients. Did you know someone with myeloma is 5x more likely to develop an infection than the general population? Infections can also be more severe and life threatening due to the impact of myeloma and myeloma treatments on the immune system.

This is why we’re launching a series of Q&A and easy-to-read infographics covering topics that patients and their families need to know about myeloma infection risk and how to avoid and treat infections.

Knowledge is a great defence against infection. Read our new materials to get informed and stay protected.

https://www.mpeurope.org/about-myeloma/infections-and-myeloma/

10/09/2025

Don't miss our 'Reducing Infection Risk in Myeloma' webinar tomorrow!

Thursday, 11 September | 17:00-18:00 CET

Join our guests, clinical nurse Jackie Quinn and myeloma patient Mimi Quinn (unrelated, despite the shared surname), for essential insights on managing infection risk – combining expert clinical knowledge with real patient experience.

Plus, if you haven't yet, there's still time to register!

| Learn more about myeloma and AL amyloidosis at the website.

08/09/2025

The MPE Spanish member organisation AELCLÉS held its Annual Masterclass last weekend with the participation of its members, sponsors and leading speakers who addressed several key topics for patients. These included the latest updates in haematological diseases, the impact of infections in blood cancers, challenges in lymphoma, leukaemia, myeloma and AL amyloidosis, as well as how to create patient evidence, among others.

During the event, Aelclés Agrupación Española contra la Leucemia y Enfermedades de la Sangre presented its new myeloma and AL amyloidosis workgroup, created with the support of the MPE Scholarship and Capacity Building Programme, in a session moderated by MPE Head of Communications, Ana Vallejo. The group will work to address unmet needs in myeloma and AL amyloidosis in Spain through different projects. The first initiative will be the Spanish translation of the Myeloma and AL Amyloidosis European Clinical Trial Navigator, an online search tool designed to help patients find clinical trials for myeloma, monoclonal gammopathy of undetermined significance (MGUS), smouldering myeloma (SMM), and AL amyloidosis across Europe.

Congratulations to AELCLÉS for a successful Masterclass!

06/09/2025

MPE’s member organisation in Poland, Fundacja Carita im. Wiesławy Adamiec, successfully held its 5th “Rally for Health” today in Poznań, Poland.

The aim of the Rally for Health is to raise awareness and educate the public about blood cancers. As part of the event, Fundacja Carita organised 5 km and 20 km bike rallies, which saw participation from patients, advocates, healthcare professionals, and industry partners—all united in their commitment to raising awareness.
In collaboration with several health organisations, the event also featured booths offering free health check-ups. A key highlight was the partnership between Fundacja Carita and Stowarzyszenie Kierunek Zdrowie, another MPE member in Poland, to host haematology consultation booths. Leading haematologists, including Prof. Dominik Dytfeld, were available to provide free consultations to anyone seeking expert advice.
MPE’s President, Leonardi, and Linda Christopher, Head of Member and Patient Community Programmes, attended the event to show their support for Fundacja Carita and the wider patient community.
Despite challenging weather conditions, the event was a great success, bringing together diverse stakeholders to raise awareness about myeloma and other blood disorders, and demonstrating the strength and solidarity of the community.

04/09/2025

ONE WEEK TO GO!

It's not long until our 'Reducing Infection Risk in Myeloma' webinar.

Don't miss this essential webinar for the myeloma community, offering clinical and lived perspectives from guest speakers Jackie Quinn, Clinical Nurse, and Mimi Quinn, myeloma patient (no relation).

Reserve your place now to join us next Thursday, 11 September, from 17:00 – 18:00 CET for vital insights on managing infection risk in myeloma.

Sign up now!
https://www.mpeurope.org/myeloma-and-infection-clinical-and-lived-perspectives-webinar/

04/09/2025

Shape your myeloma care

We're excited to share our new research summary that sheds light on how decision-making currently takes place in myeloma treatment and care across Europe, and more importantly, how we can make it better for patients by spreading awareness of the benefits of shared decision-making.

Read more
https://www.mpeurope.org/shape-your-myeloma-care-new-mpe-research-highlights-the-power-of-shared-decision-making-in-myeloma-care

| Learn more about myeloma and AL amyloidosis at the website.

01/09/2025

September is Blood Cancer Awareness Month, and on the 27th, MPE holds European Myeloma Day.

Join us as we shine a light on myeloma throughout the month and the issues that matter to patients.

29/08/2025

ONE MONTH TO GO!

European Myeloma Day is fast approaching.

Join us on September 27 as we come together to Learn, Share, and Change the myeloma landscape across Europe.

Mark your calendars and watch this space for updates on how you can get involved!

22/08/2025

MYELOMA PATIENTS EUROPE ON INSTAGRAM

We're excited to announce the launch of our new Instagram channel. Give us a follow for posts related to our work, the latest treatment approvals, tips on how to live well with myeloma and news on clinical trials, plus much more!

https://www.instagram.com/myelomapatientseurope/

Myeloma Patients Europe (MPE) is here to connect, support, and empower the myeloma community across our continent and beyond.

We look forward to connecting with you on your favored channel.

20/08/2025

MPE webinar: Reducing infection risk in myeloma

MPE will host a webinar on Thursday, 11th September, from 17:00 to 18:00 CET to discuss infection risks and myeloma.

The session will feature two speakers: Jackie Quinn, Myeloma Clinical Nurse Specialist at Belfast Trust, will provide patient-friendly information on how myeloma and its treatments increase infection risk and how patients can help protect themselves against infection.

Mimi Quinn, a myeloma patient from Ireland, will provide her experience of infection during her diagnosis and treatments. She will also discuss how living with reduced immunity impacts her life.

Both speakers will be available for a Q&A session at the end of the presentations.

To find out more or book your place, visit https://www.mpeurope.org/myeloma-and-infection-clinical-and-lived-perspectives-webinar/

| Learn more about myeloma and AL amyloidosis at the website.

29/07/2025

Alongside last week’s news on belantamab mafodotin and daratumumab, there was more good news: isatuximab has been approved by the European Commission for use in transplant-eligible, newly diagnosed myeloma patients in combination with bortezomib, lenalidomide and dexamethasone.

📰 Read our full news update here:
👉 https://www.mpeurope.org/approval-for-isatuximab-for-transplant-eligible-newly-diagnosed-myeloma-patients/

| Learn more about myeloma and AL amyloidosis at the website.

25/07/2025

𝗜𝗺𝗽𝗼𝗿𝘁𝗮𝗻𝘁 𝗻𝗲𝘄𝘀 𝗳𝗼𝗿 𝘁𝗵𝗲 𝗺𝘆𝗲𝗹𝗼𝗺𝗮 𝗰𝗼𝗺𝗺𝘂𝗻𝗶𝘁𝘆!

The European Commission has today granted final authorisation for two belantamab mafodotin (Blenrep®) combinations to be used across the EU for relapsed/refractory myeloma patients who have received at least one prior line of therapy.

The two new treatment combinations now approved are:
- Blenrep plus bortezomib and dexamethasone (BVd)
- Blenrep plus pomalidomide and dexamethasone (BPd)

The approval is based on positive results from the DREAMM-7 and DREAMM-8 phase III trials, which showed extended progression-free survival compared to standard of care.

As our co-CEO Kate Morgan notes: "The more treatments we have, including new mechanisms of action such as belantamab mafodotin, the more effectively we are able to treat myeloma."

While this EU-wide marketing authorisation confirms safety and efficacy, patient access will vary greatly and depend on national healthcare system decisions. We'll continue our work with stakeholders across Europe to improve access for patients who need it.

Read more at https://www.mpeurope.org/the-european-commission-grants-final-authorisation-for-belantamab-mafodotin-blenrep-combinations-for-relapsed-refractory-myeloma-patients/

hashtag hashtag hashtag hashtag hashtag

| Learn more about myeloma and AL amyloidosis at the website.

Adres

Avenue Louise 143/4
Brussels
1050

Website

http://www.mpeurope.org/

Meldingen

Wees de eerste die het weet en laat ons u een e-mail sturen wanneer Myeloma Patients Europe nieuws en promoties plaatst. Uw e-mailadres wordt niet voor andere doeleinden gebruikt en u kunt zich op elk gewenst moment afmelden.